Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (181-190 of 280) with videos related to

Pageof 28
Sort By:
Blood|March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphomaCraig S Sauter, Matthew J Matasar, Jessica Meikle, et al.
Immunity|September 5, 1998
Helper T cell differentiation is controlled by the cell cycleJ J Bird, D R Brown, A C Mullen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2009
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceS M Edwards-Bennett, L M Jacks, C H Moskowitz, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|November 24, 2004
Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphomaQianxun Xiao, Ning Shen, Cyrus V Hedvat, et al.
British Journal of Haematology|July 6, 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationGunjan L Shah, Joachim Yahalom, Matthew J Matasar, et al.
British Journal of Haematology|February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 monthsMatthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin FailurePhilippe Armand, Margaret A Shipp, Vincent Ribrag, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 29, 1998
Control of Leishmania major by a monoclonal alpha beta T cell repertoireS L Reiner, D J Fowell, N H Moskowitz, et al.
Bone Marrow Transplantation|April 27, 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphomaC H Moskowitz, S D Nimer, J R Glassman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphomaP J Bröckelmann, H Müller, O Casasnovas, et al.
Pageof 28

Showing results (181-190 of 280) with videos related to

Sort By:
Pageof 28
Blood|March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphomaCraig S Sauter, Matthew J Matasar, Jessica Meikle, et al.
Immunity|September 5, 1998
Helper T cell differentiation is controlled by the cell cycleJ J Bird, D R Brown, A C Mullen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2009
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceS M Edwards-Bennett, L M Jacks, C H Moskowitz, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|November 24, 2004
Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphomaQianxun Xiao, Ning Shen, Cyrus V Hedvat, et al.
British Journal of Haematology|July 6, 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationGunjan L Shah, Joachim Yahalom, Matthew J Matasar, et al.
British Journal of Haematology|February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 monthsMatthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin FailurePhilippe Armand, Margaret A Shipp, Vincent Ribrag, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 29, 1998
Control of Leishmania major by a monoclonal alpha beta T cell repertoireS L Reiner, D J Fowell, N H Moskowitz, et al.
Bone Marrow Transplantation|April 27, 1999
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphomaC H Moskowitz, S D Nimer, J R Glassman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphomaP J Bröckelmann, H Müller, O Casasnovas, et al.
Pageof 28